We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 10, 2021

Liraglutide for Obesity in Those With Severe Mental Illness

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
The Use of Liraglutide 3.0 mg Daily in the Management of Overweight and Obesity in People With Schizophrenia, Schizoaffective Disorder and First Episode Psychosis: Results of a Pilot Randomised Double-Blind Placebo-Controlled Trial
Diabetes Obes Metab 2021 Feb 02;[EPub Ahead of Print], CA Whicher, HC Price, P Phiri, S Rathod, K Barnard-Kelly, K Ngianga, K Thorne, C Asher, RC Peveler, J McCarthy, RI Holt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading